SAN FRANCISCO: OpenAI has joined forces with Retro Biosciences, a longevity-focused start-up, to develop an artificial intelligence (AI) model that could extend human lifespans by up to 10 years.
According to ETX Studio, the goal is to explore how Yamanaka factors — a group of proteins that can reprogramme adult cells into pluripotent stem cells, which usually appear only during early stages of embryo development — can extend life expectancy.
The AI model, GPT-4b micro, has been specifically trained to optimise the Yamanaka factors, enhancing the efficiency and reliability of the reprogramming process. If successful, the technology could revolutionise health and ageing, offering significant advancements in life extension.
Currently, GPT-4b micro is being used exclusively for experimental purposes. OpenAI and Retro Biosciences have not indicated whether the model will eventually be available for public use.
The Sam Altman connection
The partnership highlights a deeper connection between OpenAI and Retro Biosciences—Sam Altman, OpenAI’s co-founder and CEO, is also an investor in Retro Biosciences. This collaboration aligns with Altman’s broader interests in advancing transformative technologies.
As the initiative unfolds, it underscores AI’s potential to address some of humanity’s most pressing challenges, including ageing and health deterioration./TISG
Read also: OpenAI rolls out ChatGPT-powered internet search to all users, challenging Google’s dominance
Featured image by Depositphotos (for illustration purposes only)